3-({1-[3-(1H-Imidazol-2-ylamino)-propyl]-1H-indazole-5-carbonyl}-amino)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-({1-[3-(1H-Imidazol-2-ylamino)-propyl]-1H-indazole-5-carbonyl}-amino)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
• 英文别名: (2S)-3-[[1-[3-(1H-imidazol-2-ylamino)propyl]indazole-5-carbonyl]amino]-2-[(2,4,6-trimethylphenyl)sulfonylamino]propanoic acid
• 化学式: C₂₆H₃₁N₇O₅S
• 分子量: 553.6
• InChiKey: UQSXTDKNKMCKEM-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  180
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
  申请人：Amberg Wilhelm

  公开号：US20090311266A1

  公开（公告）日：2009-12-17

  The invention relates to the use of an endothelin blocker in combination with an α v β 3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an α v β 3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.

  本发明涉及将内皮素阻滞剂与αvβ3整合素受体拮抗剂结合使用以治疗或预防疾病，特别是涉及使用一种制药组合物，包括内皮素阻塞剂和αvβ3整合素受体拮抗剂，用于治疗或预防心血管疾病，特别是用于治疗或预防血管损伤或再血管化治疗后的再狭窄，以及该制药组合物本身。
• Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy
  申请人：Geneste Herve

  公开号：US20060159678A1

  公开（公告）日：2006-07-20

  The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin α v β 3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin α v β 3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

  本发明涉及将细胞因子介导的信号通路调节剂与整合素 α v β 3 受体拮抗剂用于治疗或预防疾病，特别是涉及一种药物组合物的用途，该药物组合物由细胞因子介导的信号通路调节剂和整合素 α v β 3 v β 3 受体拮抗剂，用于治疗或预防炎症性或自身免疫性疾病，特别是治疗或预防类风湿性关节炎，以及药物组合物本身。
• COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST
  申请人：Abbott GmbH & Co. KG

  公开号：EP1239877B1

  公开（公告）日：2008-01-09